MedTrace Logo

A Controlled Surveillance of the Osteoarthritic Knee Microenvironment With Regenexx® SD Treatment

NCT02370823 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2018-03-30

No results posted yet for this study

Summary

The primary objective of this study is to determine the levels of proteins and/or cellular components of the synovial fluid that are indicative of microenvironment phenotypes of the osteoarthritic knee compared to unilateral unaffected joints pre-injection to 6 weeks post-Regenexx® SD treatment.

Conditions

  • Osteoarthritis, Knee

Interventions

PROCEDURE

Regenexx SD

stem cell treatment

Sponsors & Collaborators

  • Regenexx, LLC

    lead INDUSTRY

Principal Investigators

  • Christopher Centeno, MD · Centeno-Schultz Clinic

Eligibility

Min Age
35 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2018-03-31
Completion
2018-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02370823 on ClinicalTrials.gov